Mecamylamine
From Wikipedia, the free encyclopedia
 |
|
|
Mecamylamine
|
|
| Systematic (IUPAC) name | |
| N,2,3,3-tetramethylnorbornan-2-amine | |
| Identifiers | |
| CAS number | 82924-03-6 |
| ATC code | C02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C11H21N |
| Mol. mass | 167.291 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 40% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
℞ Prescription only |
| Routes | Oral |
Mecamylamine is a nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Mecamylamine is also sometimes used as an anti-addictive drug to help people stop smoking tobacco, and is now more widely used for this application than it is for lowering blood pressure. This effect is thought to be due to it blocking α3β4 nicotinic receptors in the brain.
In a recent double-blind, placebo controlled trial in patients with major depression, mecamylamine appears to have efficacy as an augmentation therapy. This was the first substantive evidence that compounds where the primary pharmacology is antagonism to neuronal nicotinic receptors will have antidepressant properties.
|
||||||||||||||||||||
 |
This article about an amine is a stub. You can help Wikipedia by expanding it. |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
